Americas: Japan pledges $2.7 million to tackle Chagas:
This article was originally published in Clinica
Executive Summary
Improvements in epidemiological surveillance and research are key features of a $2.7m investment by the Japanese International Co-operation Agency (JICA) to help tackle Chagas disease in Central America. The investment will be made over five years with the aim of interrupting transmission of the disease by 2010. The move has been welcomed by the Pan American Health Organization (PAHO), which has helped co-ordinate efforts already underway in Honduras, El Salvador and Guatemala. Around 18 million people are affected by the disease across Latin America and 100 million are considered at high risk. Prophylactic control of the disease is not possible, due to the lack of a suitable vaccine, thus making diagnosis-based therapy the key to tackling the disease. Chagas poses a heavy burden on health systems: In 1998, it was considered responsible for 20% of all chronic heart disease diagnosed in Honduras.
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.